Dopamine D2 receptor imaging in gilles de la Tourette syndrome

Acta Neurologica Scandinavica

Volumn 101, Issue 3, 2000, Pages 165-17l

  Muller Vahl K R ^a,b   Berding, G ^a   Kolbe, H ^a   Meyer, G J ^a   Hundeshagen, H ^a   Dengler, R ^a   Knapp, W H ^a   Emrich, H M ^b  

^a Department of Neurology ^*  (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Dopamine receptor; Gilles de la Tourette syndrome; IBZM SPECT; Pathology; Tics

Indexed keywords

3 IODO 2 HYDROXY 6 METHOXY N ((1 ETHYL 2 PYRROLIDINYL)METHYL)BENZAMIDE; 3-IODO-2-HYDROXY-6-METHOXY-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)BENZAMIDE; BENZAMIDE DERIVATIVE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; PIMOZIDE; PYRROLIDINE DERIVATIVE; IODINE 123; NEUROLEPTIC AGENT; POSTSYNAPTIC RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; BINDING COMPETITION; CHILD; CORPUS STRIATUM; FEMALE; FRONTAL LOBE; GILLES DE LA TOURETTE SYNDROME; HOSPITALIZATION; HUMAN; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; HYPOTHESIS; RECEPTOR BINDING; RECEPTOR DENSITY; SCHOOL CHILD; TIC;

ADOLESCENT; ADULT; BENZAMIDES; BINDING, COMPETITIVE; CHILD; CONTRAST MEDIA; CORPUS STRIATUM; DOPAMINE ANTAGONISTS; FEMALE; FRONTAL LOBE; HUMANS; MALE; MIDDLE AGED; PIMOZIDE; PYRROLIDINES; RECEPTORS, DOPAMINE D2; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOURETTE SYNDROME;

EID: 0033622191     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0404.2000.101003165.x     Document Type: Article

References (33)

1. 1. Robertson MM. Annotation: Gilles de la Tourette syndrome - An update. J Child Psychol Psychiatry 1994;35: 597-611.
2. 2. Müller-Vahl KR, Kolbe H, Dengler R. Gilles de la Tourette Syndrom Eine aktuelle Übersicht. Akt Neurol 1997;24:12-19.
3. 3. Shapiro E, Shapiro AK, Fulop G et al. Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 1989;46:722-30.
4. 4. Golden GS. The relationship between stimulant medication and tics. Pediatr Ann 1988;17:405-6, 8.
5. 5. Singer HS, Butler IJ, Tune LE, Seifert WE, Coyle JT. Dopaminergic dysfunction in Tourette syndrome. Ann Neurol 1982;12:361-6.
6. 6. George MS, Robertson MM, Costa DC et al. Dopamine receptor availability in Tourette's syndrome. Psychiatry Res 1994;55:193-203.
7. 7. Turjanski N, Sawle GV, Playford ED et al. PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome. J Neurol Neurosurg Psychiatry 1994;57:688-92.
8. 8. Wong DF, Singer HS, Brandt J et al. D2-like dopamine receptor density in Tourette syndrome measured by PET. J Nucl Med 1997;38:1243-7.
9. 9. Wolf SS, Jones DW, Knable MB et al. Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science 1996;273: 1225-7.
10. 10. Nee LE, Polinsky RJ, Ebert MH. Tourette syndrome: clinical and family studies. Adv Neurol 1982;35:291-5.
11. 11. Goetz CG, Tanner CM, Stebbins GT, Leipzig G, Carr WC. Adult tics in Gilles de la Tourette's syndrome: description and risk factors. Neurology 1992;42:784-8.
12. 12. Erenberg G, Cruse RP, Rothner AD. The natural history of Tourette syndrome: a follow-up study. Ann Neurol 1987; 22:383-5.
13. 13. Bruun RD, Budman CL. The natural history of Tourette syndrome. Adv Neurol 1992;58:1-6.
14. 14. Kung HF, Alavi A, Chang W et al. In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans. J Nucl Med 1990;31:573-9.
15. 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease. Nucl Med Commun 1991;12: 699-707.
16. 16. Brücke T, Podreka I, Angelberger P et al. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 1991; 11:220-8.
17. 123I-IBZM in humans. Ann Nucl Med 1993;7:29-38.
18. 18. Shapiro AK, Shapiro ES, Young JG, Feinberg TE. Signs, symptoms, and clinical course. In: Shapiro AK, Shapiro ES, Young JG, Feinberg TE, eds. Gilles de la Tourette Syndrome. 2nd ed. New York: Raven Press, 1988;127-93.
19. 19. Butler IJ, Koslow SH, Seifert WE, Caprioli RM, Singer HS. Biogenic amine metabolism in Tourette syndrome. Ann Neurol 1979;6:37-9.
20. 20. Cohen DJ, Shaywitz BA, Caparulo BK, Young JG, Bowers MB Jr. Chronic, multiple tics of Gilles de la Tourette's disease. CSF acid monoamine metabolites after probenecid administration. Arch Gen Psychiatry 1978;35:245-50.
21. 21. Singer HS, Hahn I-H, Moran T. Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndrome. Ann Neurol 1991;30:558-62.
22. 123I]β-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am J Psychiatry 1995;152: 1359-61.
23. 23. Wong DF, Singer H, Marenco S et al. Dopamine transporter reuptake sites measured by (C11)WIN 35,428 PET imaging are elevated in Tourette syndrome. J Nucl Med 1994;35:130P(abstract).
24. 24. Kessler RM, Ansari MS, de Paulis T et al. High affinity dopamine D2 receptor radioligands. I. Regional rat brain distribution of iodinated benzamides. J Nucl Med 1991; 32:1593-1600.
25. 25. Kung HF, Pan S, Kung MP et al. In vitro and in vivo evaluation of (123I)IBZM: a potential CNS D-2 dopamine receptor imaging agent. J Nucl Med 1989;30:88-92.
26. 26. Camps M, Cortes R, Gueye B, Probst A, Palacios JM. Dopamine receptors in human brain: autoradiographic distribution of D2 sites. Neuroscience 1989;28:275-90.
27. 3H]raclopride to rat and human brain membranes. J Neurochem 1990;55:2048-57.
28. 28. Schwarz J, Antonini A, Tatsch K, Kirsch CM, Oertel WH, Leenders KL. Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism. Nucl Med Commun 1994;15:806-13.
29. 29. Verhoeff NPLG, Costa DC, Ell PJ et al. Dopamine D2-receptor imaging with dynamic I-123 IBZM SPECT in patients with schizophrenia or HIV encephalopathy. Nucl Med 1991;Suppl 27:207-12.
30. 30. Verhoeff NP, Brucke T, Podreka I, Bobeldijk M, Angelberger P, Van Royen EA. Dynamic SPECT in two healthy volunteers to determine the optimal time for in vivo D2 dopamine receptor imaging with 123I-IBZM using the rotating gamma camera. Nucl Med Commun 1991;12: 687-97.
31. 31. Kurlan R, McDermott MP. Rating tic severity. In: Kurlan R, ed. Handbooks of Tourette's syndrome and related tic and behavioral disorders. New York, Basel, Hong Kong: Marcel Dekker Inc, 1993;199-220.
32. 2 receptor blockade by Flunarizine and Cinnarizine explains extra-pyramidal side effects. A SPECT study: J Cereb Blood Flow Metab 1995;15:513-18.
33. 123I-IBZM Single Photon Emission Computed Tomography study. Br J Psychiatry 1994;164:16-26.